Search results for "Diphosphonate"

showing 10 items of 124 documents

Targeting the mevalonate pathway for improved anticancer therapy.

2009

The mevalonate pathway is important for the generation of isoprene moieties thereby providing the basis for the biosynthesis of molecules required for maintaining membrane integrity, steroid production and cell respiration. Additionally, isoprene precursors are indispensable for the prenylation of regulatory proteins such as Ras and Ras-homologous (Rho) GTPases. These low molecular GTP-binding proteins play key roles in numerous signal transduction pathways stimulated upon activation of cell surface receptors by ligand binding. Thus, Ras/Rho proteins eventually regulate cell proliferation, tumor progression and cell death induced by anticancer therapeutics. Lipid modification of Ras/Rho pro…

rho GTP-Binding ProteinsCancer Researchmedicine.medical_treatmentProtein PrenylationMevalonic AcidAntineoplastic AgentsGTPaseModels BiologicalSteroidDrug Delivery SystemsPrenylationCell surface receptorNeoplasmsDrug DiscoverymedicineAnimalsHumansPharmacologyCell DeathDiphosphonatesChemistryCell growthMembrane ProteinsDimethylallyltranstransferaseCell biologyOncologyras ProteinsMevalonate pathwayLipid modificationSignal transductionHydroxymethylglutaryl-CoA Reductase InhibitorsSignal TransductionCurrent cancer drug targets
researchProduct

Reaction of 3-Amino-1,2,4-Triazole with Diethyl Phosphite and Triethyl Orthoformate: Acid-Base Properties and Antiosteoporotic Activities of the Prod…

2017

The reaction of diethyl phosphite with triethyl orthoformate and a primary amine followed by hydrolysis is presented, and the reaction was suitable for the preparation of (aminomethylene)bisphosphonates. 3-Amino-1,2,4-triazole was chosen as an interesting substrate for this reaction because it possesses multiple groups that can serve as the amino component in the reaction-namely, the side-chain and triazole amines. This substrate readily forms 1,2,4-triazolyl-3-yl-aminomethylenebisphosphonic acid (compound 1) as a major product, along with N-ethylated bisphosphonates as side products. The in vitro antiproliferative effects of the synthesized aminomethylenebisphosphonic acids against J774E m…

Models Molecularorganophosphorus chemistryPhosphitesBase (chemistry)FormatesTriazoleMolecular ConformationPharmaceutical ScienceOsteoclastsApoptosis010402 general chemistry01 natural sciencesAnalytical Chemistrylcsh:QD241-441chemistry.chemical_compoundHydrolysisMicelcsh:Organic chemistryCell Line TumorDrug DiscoveryOrganic chemistryAnimals3-Amino-124-triazolePhysical and Theoretical Chemistrycrystallographychemistry.chemical_classificationBone Density Conservation AgentsDiphosphonates010405 organic chemistryChemistryCommunicationOrganic ChemistrySubstrate (chemistry)Triazolesthree-component reactionTriethyl orthoformateUV-Vis spectroscopyMagnetic Resonance Imaging0104 chemical sciencesP-containing drugstriazoleChemistry (miscellaneous)potentiometryaminomethylenebisphosponatesMolecular Medicineanti-proliferative activityAmine gas treatingpH-titrationbisphosphonic acidsMolecules (Basel, Switzerland)
researchProduct

Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.

2006

Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the > circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 > (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in > patients with bone metastasis (BMTS) and the possible correlation with the symptomatic > response induced by this drug in these patients were evaluated. Patients and Methods: > Proteinase levels were determined by enzyme-linked immunosorbent assay (ELISA) in the > plasma of 30 patients with painful bone metastases from breast or prostate cancer > undergoing multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy subjects > (HS) of…

Aged 80 and overMaleBone Density Conservation AgentsDiphosphonatesZoledronic > acidImidazolesProstatic NeoplasmsBone NeoplasmsBreast NeoplasmsMiddle AgedProteinaseZoledronic AcidCathepsin BMatrix > metalloproteinase-9Matrix Metalloproteinase 9Matrix metalloproteinase-2Bone metastasiBisphosphonates; Bone metastasis; Cathepsin B; Matrix metalloproteinase-2; Matrix > metalloproteinase-9; Proteinases; Urokinase-type plasminogen activator; Zoledronic > acidHumansMatrix Metalloproteinase 2BisphosphonateFemaleUrokinase-type plasminogen activatorAged
researchProduct

Determination of renal tissue ibandronate levels in rats with normal and mildly impaired renal function

2013

After entering the blood, bisphosphonates are immediately bound to bone or excreted unchanged by the kidney. During renal excretion about 0.5% of administrated dosage remains in kidney tissue. The renal tissue level of bisphosphonates (RTL) decreases over time and remains at about 0.15% after 3weeks, but the influence of renal insufficiency (RI) is unclear.We investigated the influence of mild to moderate RI on RTL of ibandronate (IBD). First a method for determination of RTL was implemented and validated. We measured RTL in rats with normal renal function (SHAM) and after unilateral nephrectomy (UNX). In each case one SHAM and one UNX groups received one or alternatively 9 times every 3wee…

medicine.medical_specialtyTime FactorsUrologyKidneyToxicologySeverity of Illness IndexImpaired renal functionNormal renal functionmedicineAnimalsTissue DistributionRenal InsufficiencyRats WistarIbandronic AcidPharmacologyKidneyBone Density Conservation AgentsDiphosphonatesbusiness.industryRenal tissueUnilateral nephrectomyRatsSurgeryDisease Models Animalmedicine.anatomical_structureRenal physiologyFemalebusinessHalf-LifeJournal of Pharmacological and Toxicological Methods
researchProduct

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

2006

Background:  Patients treated with bisphosphonates because of bone metastases have been shown to develop osteonecrosis of the jaws. In the present study, we examined the histologic findings of these cases. As similarities between this disorder and infected osteoradionecrosis (IORN) are described, both lesions were compared. Methods:  We investigated eight patients with bisphosphonate treatment and osteonecrosis (four female, four male; median age: 65.6 years; cancer: multiple myeloma in five patients, breast cancer in three patients; mandibular involvement in five patients, maxillar involvement in three cases), and 10 patients suffering from IORN (all male; median age: 61.3 years; cancer: s…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyOsteoradionecrosisAdenoid cystic carcinomamedicine.medical_treatmentAntineoplastic AgentsBone NeoplasmsBone resorptionPathology and Forensic MedicineBreast cancermedicineCarcinomaActinomycesHumansMultiple myelomaAgedAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisCancerBisphosphonateMiddle Agedmedicine.diseaseCarcinoma Adenoid CysticOtorhinolaryngologyOsteoradionecrosisCarcinoma Squamous CellPeriodonticsFemaleOral SurgerybusinessJaw DiseasesJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020

2020

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SI…

bisphosphonateOral SurgeonHealth Toxicology and Mutagenesislcsh:MedicineMRONJantiangiogenic agents; antiresorptive drugs; bisphosphonates; cancer; denosumab; dentistry; MRONJ; oral surgery; osteoporosis; prevention models; bisphosphonate-associated osteonecrosis of the jaw; bone density conservation agents; diphosphonates; humans; Italy; quality of life0302 clinical medicineprevention modelCancerantiangiogenic agentsdentistryBone Density Conservation AgentsDiphosphonatesConference ReportBisphosphonatesAntiresorptive DrugsDenosumabItaly030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabmedicine.drugoral surgerymedicine.medical_specialtyOral surgery03 medical and health sciencesOral surgeryAntiangiogenic agentsOral and maxillofacial pathologymedicinecancerHumansantiangiogenic agentantiresorptive drugsIntensive care medicinePrevention modelsbisphosphonatesantiresorptive drugAntiangiogenic agentsbusiness.industrylcsh:RPublic Health Environmental and Occupational Healthdenosumab030206 dentistrymedicine.diseaseosteoporosisAntiresorptive drugsDentistryOsteoporosisprevention modelsbusinessAntiangiogenic agents; Antiresorptive drugs; Bisphosphonates; Cancer; Denosumab; Dentistry; MRONJ; Oral surgery; Osteoporosis; Prevention models
researchProduct

A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting

2016

Radiolabeled bisphosphonates are commonly used in the diagnosis and therapy of bone metastases. Blood clearance of bisphosphonates is usually fast and only 30%-50% of the injected activity is retained in the skeleton, while most of the activity is excreted by the urinary tract. A longer blood circulation may enhance accumulation of bisphosphonate compounds in bone metastases. Therefore, a chemically modified macrocyclic bisphosphonate derivative with an additional human albumin binding entity was synthesized and pharmacokinetics of its complex was evaluated. The DOTA-bisphosphonate conjugate BPAMD was compared against the novel DOTAGA-derived albumin-binding bisphosphonate DOTAGA(428-d-Lys)…

MaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentSerum albuminGallium RadioisotopesBone and Bones030218 nuclear medicine & medical imagingHeterocyclic Compounds 1-Ring03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoInternal medicinemedicineAnimalsHumansDOTATissue DistributionRadiology Nuclear Medicine and imagingRats WistarSerum AlbuminDiphosphonatesbiologyAlbuminDiphosphonatesBisphosphonateHuman serum albuminRatsDurapatiteEndocrinologychemistryPositron-Emission Tomography030220 oncology & carcinogenesisbiology.proteinMolecular MedicineAdsorptionEx vivomedicine.drugNuclear Medicine and Biology
researchProduct

Structure-Dependent Dissolution and Restructuring of Calcite Surfaces by Organophosphonates

2017

Organophosphonates are well-known to strongly interact with the surfaces of various minerals, such as brucite, gypsum, and barite. In this work, we study the influence of six systematically varied organophosphonate molecules (tetraphosphonates and diphosphonates) on the dissolution process of the (10.4) surface of calcite. In order to pursue a systematic study, we have selected organophosphonates that exhibit similar structural features, but also systematic architectural differences. The effect of this class of additives on the dissolution process of the calcite (10.4) surface is evaluated using in situ dynamic atomic force microscopy. For all of the six organophosphonate derivatives, we ob…

CalciteGypsumAtomic force microscopyBruciteDiphosphonates02 engineering and technologyGeneral Chemistryengineering.material010402 general chemistry021001 nanoscience & nanotechnologyCondensed Matter Physics53001 natural sciences0104 chemical scienceschemistry.chemical_compoundCrystallographychemistryChemical engineeringengineeringMoleculeGeneral Materials ScienceOrganophosphonates0210 nano-technologyDissolutionCrystal Growth & Design
researchProduct

Toxicity of a dental adhesive compared with ionizing radiation and zoledronic acid

2015

Background: To determine the toxicity of aqueous dilutions of a universal self-priming dental adhesive (DA) and comparing these with those elicited by exposure to ionizing radiation (IR), Zoledronic acid (Z) treatment and the synergic effects of the combined treatment with IR+Z. Material and Methods: The genotoxic effect of DA was determined by the increase in the frequency of micronuclei in cytokinesis-blocked in cultured human lymphocytes before and after exposure to 2Gy of X-rays. The cytotoxic effect was studied by using the MTT cell viability test in normal prostate cell lines (PNT2) after exposure to different X-ray doses (0Gy-20Gy). The cell lines divided into different groups and tr…

Programmed cell deathDental CementsOdontologíaPharmacologymedicine.disease_causeZoledronic AcidIonizing radiationToxicologyPolymethacrylic AcidsRadiation IonizingToxicity TestsmedicineCytotoxic T cellHumansViability assayLymphocytesGeneral DentistryCells CulturedOral Medicine and PathologyDiphosphonatesChemistryResearchImidazoles:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludIn vitroOtorhinolaryngologyToxicityMicronucleus testUNESCO::CIENCIAS MÉDICASSurgeryGenotoxicity
researchProduct

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

2012

There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. INTRODUCTION: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. METHODS: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who w…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismONJDentistryOsteoporosis; fractures; biphosphonatesAdministration OralBisphosphonates Nested case–control study Osteonecrosis of the jaw Osteoporotic fracturesOSTEPOROSISRisk AssessmentAssociationADMINSTRATIVE DATABASESnested case-control studySettore MED/28 - Malattie OdontostomatologicheClaims dataMedicineHumansnested case-control study; osteoporotic fractures; osteonecrosis of the jaw; bisphosphonatesWomenbisphosphonatesAgedSecondary preventionAged 80 and overOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryMiddle Agedmedicine.diseaseOral BisphosphonateNecrosiosteonecrosis of the jawItalyClaims DataCase-Control StudiesOrthopedic surgeryBisphosphonates; Osteonecrosis of the jaw; Osteoporotic fractures; Nested case-control studyBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryProfileBisphosphonate therapyMedical Record LinkagebusinessOsteonecrosis of the jawOsteoporotic Fractures
researchProduct